Dermatology Times, June 2021 (Vol. 42, No. 6)

From oat oil to acupuncture to prebiotics, there are many topical, oral, and manual options.

Patients with anxiety/depression and psoriatic arthritis (PsA) are much less likely to achieve long-term remission. Mental health comorbidities need to be a more important part of PsA treatment.

Nasal papules that are histologically indistinguishable from angiofibroma may be a sequela of acne.

These ratios will help you determine the level of financial stability of your practice and help you make better decisions for your future.

It’s always a good time to do a financial review. You’ll make sure your savings and investments are aligned with your goals and reduce income taxes.

In this month's Legal Eagle column, David J. Goldberg, MD, JD, dives into wrong-site surgeries and malpractice lawsuits.

American Academy of Dermatology’s updated guidelines on acne will cover dermatology’s hottest issues, from dosing and monitoring established medications to exploring new antibiotics and addressing antibiotic stewardship.

Biologic therapy has proven very useful in treating an increasing number of dermatologic diseases and conditions. However, caution is warranted for patients with chronic infectious diseases.

A higher prevalence of vitamin D deficiency in people of color may be contributing to a higher burden of COVID-19 in minority populations. Dermatologists are encouraged to address vitamin D status in patients and recommend supplementation, which might have other health benefits.

Study results reveal that nanosecond pulsed electric field therapy alters the C. acnes biofilm to enable better treatment penetration.

New regulations, latest absorption data, and updates on environmental and health impacts are shaping the world of photoprotection.

BCC, SCC treatments take advantage of refinements in established techniques and new technology.

Trichoscopy, which is based on dermoscopy, can be a valuable tool for diagnosing conditions that cause hair loss and inflammatory scalp disease.

Experts evaluate efficacy and safety of regenerative skin care products.

Nonprescription moisturizers and cleansers can play an integral role in delivering positive treatment outcomes for patients with rosacea.

After data from a phase 3 study, FDA opens potential for apremilast to be the first and only approved oral therapy for mild to moderate plaque psoriasis.

A phase 3 trial produced results on the efficacy of different doses of the JAK1 inhibitor.

Deucravacitinib meets primary end points for treating moderate to severe psoriasis.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date for bimekizumab (UCB) for the treatment of psoriasis.